MULLINS v. ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.

CourtDistrict Court, D. New Jersey
DecidedFebruary 27, 2020
Docket1:19-cv-15043
StatusUnknown

This text of MULLINS v. ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (MULLINS v. ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
MULLINS v. ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD., (D.N.J. 2020).

Opinion

[C.A. No. 19-14891, Doc. No. 6] [C.A. No. 19-15043, Doc. No. 8]

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY CAMDEN VICINAGE

IN RE: VALSARTAN N- Master No. 19-2875(RBK/JS) NITROSODIMETHYLAMINE

(NDMA), LOSARTAN, and This Order Pertains to: IRBESARTAN PRODUCTS

LIABILITY LITIGATION

Marcia Cantrell v. Zhejiang Civil No. 19-14891(RBK/JS) Huahai Pharmaceutical Co.,

LTD., et al.

James Mullins v. Zhejiang Civil No. 19-15043(RBK/JS) Huahai Pharmaceutical Co., LTD., et al.

MEMORANDUM OPINION AND ORDER This matter is before the Court on identical Motions to Withdraw as Counsel filed by the attorney for two individual personal injury plaintiffs. Oral argument is not necessary. Fed. R. Civ. P. 78; L. Civ. R. 78.1. For the reasons to be discussed, counsel’s motions are DENIED. Background This Multidistrict Litigation (“MDL”) arises out of plaintiffs’ alleged ingestion of “valsartan-containing drugs” containing impurities. In July 2019, plaintiffs directly filed in this District essentially identical complaints alleging they developed colon cancer “as a result of taking an adulterated, misbranded, and unapproved medication designed, manufactured, marketed, distributed, packaged, and sold by Defendants.” See Complaints ¶2. Plaintiffs filed court-approved “Short Form

Complaints” on September 11, 2019.1 The docket reveals that plaintiffs’ counsel currently represents at least thirty-three (33) individual plaintiffs, each of whom filed a separate personal injury complaint. On February 14, 2019, the Judicial Panel on Multidistrict Litigation (“JPML”) centralized in this court the valsartan cases filed in federal courts around the country.2 Since that time the Court and parties have worked diligently to organize and manage

the litigation. On October 3, 2019 the Court entered Case Management Order No. 16 [Doc. No. 249] which approved “Fact Sheets” to be answered by all personal injury plaintiffs. Plaintiffs who do not answer the Fact Sheets are subject to a “Show Cause Process” that may ultimately result in the dismissal of their cases. Although not explicitly set forth, the Court surmises counsel’s motions arise out of her unsuccessful attempts to contact her clients in order to answer plaintiffs’ Fact Sheets. Plaintiffs’ counsel filed identical pro forma Motions to Withdraw on January 15, 2020. The Court summarily denied the

1 Cantrell’s SFC alleges she has “precancerous colon polyps.” Mullins alleges he contracted colon cancer. 2 On December 18, 2019 the JPML expanded this MDL to include losartan and irbesartan. motions the next day because “counsel’s bare-bones motion[s] provide[d] no facts or basis for the Court to determine whether counsel’s motion[s] should be granted.” Plaintiffs’ counsel re-

filed the instant two-page unsupported Motions to Withdraw on February 4, 2020. The motions do not add much to what was originally filed. Ordinarily, given counsel’s perfunctory motions they would be summarily denied. However, since the subject of counsel’s motions are capable of repetition, and counsel did not “get the message” after the Court’s previous ruling, a more detailed discussion is appropriate. As noted, counsel’s motions are perfunctory. The motions

merely state in conclusory language that “counsel has not been able to make contact with Plaintiff[s].” Although counsel writes she has made “reasonable attempts” to notify plaintiffs that failure to return calls and communications will result in a Motion to Withdraw, no supporting facts are provided. The same is true for counsel’s statement that she has used “reasonable efforts” to determine if the plaintiffs moved. Counsel merely writes “upon information and belief, the plaintiff[s] still remain[] at the same address[es].” Counsel concludes she is “without authority to proceed” and, therefore, requests permission to withdraw so that plaintiffs may attempt to obtain substitute counsel. Discussion

Pursuant to L. Civ. R. 102.1, unless other counsel is substituted, withdrawal of counsel requires leave of court. Rusinow v. Kamara, 920 F. Supp. 69, 71 (D.N.J. 1996). In deciding whether to permit an attorney to withdraw, the Court should consider: 1) the reasons why withdrawal is sought, 2) the prejudice withdrawal may cause to other litigants, 3) the harm withdrawal might cause to the administration of justice, and 4) the degree to which withdrawal will delay the resolution of the case. Ultimately, whether to permit withdrawal is within the Court’s discretion. Id. at 71. Further, the Court may refuse to permit

an attorney to withdraw despite a showing of good cause. Haines v. Liggett Group, Inc., 814 F. Supp. 414, 422-23 (D.N.J. 1993). In this District courts look to the New Jersey Rules of Professional Conduct (“RPC”) with regard to issues of professional conduct. “When interpreting the RPC, the Court looks to New Jersey’s state courts’ interpretation of the RPC as primary authority and modifies it when required by federal law.” Delso v. Trustees for Ret. Plan for Hourly Employees of Merck & Co., Inc.,

C.A. No. 04-3009 (AET), 2007 WL 766349, at *5 (D.N.J. March 6, 2007). Here, counsel argues she is unable to communicate with her clients and, therefore, her motions should be granted. Although not set forth, counsel presumably seeks to withdraw pursuant to RPC 1.16(b)(5),(6), or (7). RPC 1.16(b)(5) provides that a lawyer may withdraw from representing a client if “the client fails substantially to fulfill an obligation to the lawyer regarding the

lawyer’s services and has been given reasonable warning that the lawyer will withdraw unless the obligation is fulfilled.” RPC 1.16(b)(6) provides that a lawyer may withdraw if the representation “has been rendered unreasonably difficult by the client.” RPC 1.16 (b)(7) provides that a lawyer may withdraw for “other good cause.” The Court agrees that ordinarily if clients knowingly and willingly refuse to communicate and cooperate with their lawyer

the lawyer may withdraw after giving adequate written notice to the client. See First Franklin Fin. Corp. v. Rainbow Mortg. Corp., C.A. No. 07-5440 (JBS/AMD), 2008 WL 11381896, at *2 (D.N.J. Oct. 24, 2008) (citing Ramada Worldwide Inc. v. NPR Hospitality Inc., C.A. No. 06-4966, 2008 WL 163641, at *2 (D.N.J. Jan. 16, 2008)(good cause to withdraw as counsel exists where a lawyer is unable to contact his clients and the clients fail to fulfill the obligation to cooperate and assist in their defense). The problem with counsel’s motions, however, is that the motions are not supported by any facts. The Court does not know, for example, if counsel attempted to communicate with her clients by phone, mail, email or in-person. Nor does the Court know when counsel’s communications

took place or how many times the communications were allegedly ignored. In addition, the Court does not know what efforts counsel took to learn whether her clients moved or endured an unexpected event that rendered them unable to communicate for a finite period

of time. In short, counsel’s motions are too general and cursory to grant. The motions do not enable the Court to legitimately conclude that counsel’s clients abandoned the case. Based on the present record, it is just as likely that counsel’s clients inadvertently or otherwise innocently failed to respond to communications as it is they deliberately ignored counsel. As the Court already ruled, it will not permit counsel to withdraw based on a “bare-bones” record.

The judiciary has the duty to preserve the fiduciary responsibility that lawyers owe their clients. Cohen v. Radio- Electronics Officers Union, Dist. 3, NMEBA, 146 N.J. 140, 155 (1996).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re Honig
89 A.2d 411 (Supreme Court of New Jersey, 1952)
Rusinow v. Kamara
920 F. Supp. 69 (D. New Jersey, 1996)
Haines v. Liggett Group, Inc.
814 F. Supp. 414 (D. New Jersey, 1993)
Cohen v. Radio-Electronics Officers Union District 3
679 A.2d 1188 (Supreme Court of New Jersey, 1996)
In Re Brown
443 A.2d 675 (Supreme Court of New Jersey, 1982)
Estate of Spencer v. Gavin
946 A.2d 1051 (New Jersey Superior Court App Division, 2008)
McDaniel v. Daiichi Sankyo, Inc.
343 F. Supp. 3d 427 (U.S. District Court, 2018)
Garrett v. Matisa
927 A.2d 177 (New Jersey Superior Court App Division, 2007)

Cite This Page — Counsel Stack

Bluebook (online)
MULLINS v. ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD., Counsel Stack Legal Research, https://law.counselstack.com/opinion/mullins-v-zhejiang-huahai-pharmaceutical-co-ltd-njd-2020.